过氧化还原蛋白 (Prxs) 是一种普遍表达的抗氧化酶家族，可以促进或抑制肿瘤发生，具体取决于癌症类型和 Prx 亚型。 Prx2是典型的Prx，在肿瘤发生和肿瘤进展中具有双重作用。然而，Prx2的表达及其在宫颈癌中的确切作用仍有待阐明。因此，本研究旨在探讨Prx2的表达及其与宫颈鳞状细胞癌（CSCC）进展和预后的关系。在本研究中，从华中科技大学同济医学院附属荆州中心医院（中国荆州）的病历系统收集了105例诊断为CSCC的患者的临床病理资料。通过免疫组化染色，也在105个CSCC组织和40个癌旁组织中检测到Prx2蛋白。然后分析Prx2表达与CSCC临床病理特征、血管内皮生长因子A（VEGF-A）表达和微血管密度（MVD）之间的关系。还使用单变量和多变量分析评估无进展生存期（PFS）。本研究结果表明，与癌旁组织相比，CSCC组织中Prx2的表达上调（P<0.001）。此外，较高的Prx2表达与较大的间质侵犯深度（P=0.023）和阳性淋巴管间隙侵犯（P=0.044）相关，而Prx2表达水平与年龄、肿瘤大小、组织学分级、淋巴结无关。 （LN）转移或国际妇产科联合会（FIGO）分期（均P>0.05）。此外，Prx2表达增加与高MVD相关（P=0.016），而VEGF-A表达与Prx2表达无关（P>0.05）。 Kaplan-Meier分析显示，Prx2高表达（对数秩检验，P=0.039）、高MVD（对数秩检验，P=0.015）、较高FIGO分期（对数秩检验，P=0.021）和淋巴结转移（对数秩检验，P=0.022）分别比 Prx2 低表达、MVD 低、FIGO 分期较低和无淋巴结转移的患者的 PFS 时间更短。 Cox比例风险回归分析显示Prx2的表达[风险比（HR），2.551； 95%置信区间（CI），1.056-6.162； P=0.037]、MVD（HR，2.436；CI，1.034-5.735；P=0.042）和FIGO分期（HR，1.543；CI，1.027-2.319；P=0.037）是PFS时间的独立因素。总之，本研究结果表明，Prx2 可以作为预测 CSCC 进展和预后的潜在生物标志物，并可能成为 CSCC 抗血管生成治疗的新靶点。版权所有：© 2024 赵等人。

Peroxiredoxins (Prxs) are a ubiquitously expressed family of antioxidant enzymes that either facilitate or inhibit tumorigenesis, depending on the cancer type and Prx isoform. Prx2 is a typical Prx that has a dual role in tumorigenesis and tumor progression. However, the expression of Prx2 and its precise role in cervical cancer remains to be elucidated. Therefore, the present study aimed to investigate the expression of Prx2 and its association with the progression and prognosis of cervical squamous cell cancer (CSCC). In the present study, the clinicopathological data of 105 patients diagnosed with CSCC were collected from the medical record system at Jingzhou Central Hospital, Tongji Medical College of Huazhong University of Science and Technology (Jingzhou, China). Prx2 protein was also detected in 105 CSCC tissues and 40 adjacent peri-tumoral tissues by immunohistochemical staining. The relationships between Prx2 expression and clinicopathological features, vascular endothelial growth factor A (VEGF-A) expression and micro-vessel density (MVD) in CSCC were then analyzed. Progression-free survival (PFS) was also assessed using both univariate and multivariate analyses. The results of the present study demonstrated that the expression of Prx2 was upregulated in CSCC tissues compared with the adjacent peri-tumoral tissues (P<0.001). In addition, higher Prx2 expression was associated with greater depth of stromal invasion (P=0.023) and positive lymph vascular space invasion (P=0.044), while the Prx2 expression level was not associated with age, tumor size, histological grade, lymph node (LN) metastasis or International Federation of Gynecology and Obstetrics (FIGO) stage (all P>0.05). Furthermore, increased Prx2 expression was associated with high MVD (P=0.016), while expression of VEGF-A was not associated with Prx2 expression (P>0.05). Kaplan-Meier analysis showed that patients with high Prx2 expression (log-rank test, P=0.039), high MVD (log-rank test, P=0.015), a higher FIGO stage (log-rank test, P=0.021) and LN metastasis (log-rank test, P=0.022) had a shorter PFS time than patients with low Prx2 expression, low MVD, a lower FIGO stage and without LN metastasis, respectively. Cox proportional hazard regression analysis revealed that expression of Prx2 [hazard ratio (HR), 2.551; 95% confidence interval (CI), 1.056-6.162; P=0.037], MVD (HR, 2.436; CI, 1.034-5.735; P=0.042) and FIGO stage (HR, 1.543; CI, 1.027-2.319; P=0.037) were independent factors for PFS time. In conclusion, the results of the present study suggested that Prx2 could act as a potential biomarker for predicting CSCC progression and prognosis and could be a novel target for antiangiogenic therapy of CSCC.Copyright: © 2024 Zhao et al.